None

RANBAXY Laboratories has got the exclusive rights to market a generic version of Japanese firm Eisai Co

LUPIN Limited and Ranbaxy Laboratories along with its parent company Daiichi Sankyo have slapped patent infringement charges against each other to stop one another from launching low-cost versions of their respective original drugs in the US.

Indian Company To Become Pure Generics Drugmaker; To Retain Research Activity For Anti-Malarial Drug

RANBAXY Laboratories has transferred its research division for new drugs to Japan

THE Delhi High Court has turned down a plea by US pharma major Bristol-Myers Squibb (BMS) to ban India

RANBAXY Laboratories on Monday announced it has settled a patent dispute with Takeda Pharmaceutical allowing the Gurgaon-based drugmaker to launch its generic tablets of Takeda

RANBAXY Laboratories

Deal Could Be Aimed At Getting Access To Technology Or Manufacturing Platform
Khomba Singh NEW DELHI

Move Part Of Probe On Drug Units Which Delay Launch Of Generics
Our Bureau NEW DELHI

INDIA

DRL, Cipla Among Cos Found Involved In Overcharging By Drug Price Regulator

With demand for the antidote to H1N1 infection peaking across the world, the select Indian pharmaceutical companies are ramping up production of Tamiflu or its generic version.

Pages